This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BMB-001

Pfizer Inc.

Drug Names(s): , BMB-D001

Description: BMB-001 is a rhAAV vector that delivers a shortened, but functional copy of the dystrophin gene.

Deal Structure: Bamboo and Pfizer
In August 2016, Pfizer announced that it has acquired Bamboo Therapeutics. Pfizer previously acquired approximately 22 percent of Bamboos fully diluted equity during the first quarter of 2016 for a payment of approximately $43 million. Under the terms of this transaction, Pfizer acquired all of Bamboos remaining equity for an upfront payment of $150 million, and Bamboos selling shareholders will be eligible for potential milestone payments of up to $495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. Following the acquisition, Bamboo is now a wholly-owned subsidiary of Pfizer.


BMB-001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug